Price T Rowe Associates Inc. MD Raises Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Price T Rowe Associates Inc. MD boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 63.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,085,447 shares of the biopharmaceutical company's stock after buying an additional 810,144 shares during the period. Price T Rowe Associates Inc. MD owned approximately 1.90% of Regeneron Pharmaceuticals worth $1,485,527,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Capital International Investors grew its position in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the last quarter. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $802,036,000. Amundi increased its position in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after purchasing an additional 487,489 shares in the last quarter. Loomis Sayles & Co. L P lifted its stake in Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after purchasing an additional 393,997 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its position in Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after buying an additional 219,162 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Bernstein Bank dropped their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Citigroup cut their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Finally, Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a "buy" rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $945.32.

Regeneron Pharmaceuticals Stock Up 0.5 %

Shares of REGN stock traded up $2.88 on Friday, reaching $602.64. 964,377 shares of the company were exchanged, compared to its average volume of 724,654. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a 50-day moving average of $637.38 and a 200-day moving average of $723.83. The company has a market cap of $65.88 billion, a price-to-earnings ratio of 15.74, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $11.86 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.